TapewireFind a company

person · Reporting owner

APPLE ROBERT F

Disclosed activity across 2 companies

Tapewire entity
31503
SEC CIK
0001054942

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
KAZIA THERAPEUTICS LTDKZIA · Entity 6537DirectorJanuary 08, 2026July 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

KAZIA THERAPEUTICS LTD

Report date January 08, 2026 · Filed July 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78Direct75,000 Reported balance After 2026-01-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-01-08 · Grant · Acquired 75,000 · Balance 75,000

F1: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ANTARES PHARMA, INC.

Report date May 24, 2022 · Filed May 26, 2022

Section 16 reporting ended · disclosed 2022-05-26. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2022-05-24 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2022-05-24 · Disposition to issuer · Disposed 1,876,693 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2022-05-24 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2022-05-24 · Disposition to issuer · Disposed 611,667 · Balance 0

F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2022-05-24 transaction · row 3 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 3 · 2022-05-24 · Disposition to issuer · Disposed 374,099 · Balance 0

F4: Each Company performance restricted stock unit ("Company PSU") means any performance stock unit granted under the Company Equity Plan. At the Effective Time, each Company PSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company PSU (at the target level of performance) immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.26Direct0 Reported balance After 2022-05-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2022-05-24 · Disposition to issuer · Disposed 21,658 · Balance 0

F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.09Direct0 Reported balance After 2022-05-24 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2022-05-24 · Disposition to issuer · Disposed 56,300 · Balance 0

F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18Direct0 Reported balance After 2022-05-24 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2022-05-24 · Disposition to issuer · Disposed 288,786 · Balance 0

F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12Direct0 Reported balance After 2022-05-24 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2022-05-24 · Disposition to issuer · Disposed 773,700 · Balance 0

F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.66Direct0 Reported balance After 2022-05-24 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2022-05-24 · Disposition to issuer · Disposed 725,751 · Balance 0

F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70Direct0 Reported balance After 2022-05-24 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2022-05-24 · Disposition to issuer · Disposed 591,510 · Balance 0

F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92Direct0 Reported balance After 2022-05-24 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2022-05-24 · Disposition to issuer · Disposed 567,423 · Balance 0

F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.73Direct0 Reported balance After 2022-05-24 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2022-05-24 · Disposition to issuer · Disposed 776,617 · Balance 0

F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.42Direct0 Reported balance After 2022-05-24 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2022-05-24 · Disposition to issuer · Disposed 474,629 · Balance 0

F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.

F4: Each Company performance restricted stock unit ("Company PSU") means any performance stock unit granted under the Company Equity Plan. At the Effective Time, each Company PSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company PSU (at the target level of performance) immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.

F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 08, 2026 Filed Jul 8, 2026 20:57 UTC KAZIA THERAPEUTICS LTD KZIA · Entity 6537 GrantEmployee Stock Option (right to buy) · Derivative 75,000 $0.00 Strike: $6.78 $0.00
Disclosure

SEC source: 0001213900-26-076426 · ownership.xml · derivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: ADSs · 75,000 shares

Expires not disclosed

F1 · shares: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.exercise_date: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.expiration_date: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

Read SEC document
May 24, 2022 Filed May 26, 2022 17:23 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Disposition to issuerStock Option (right to buy) · Derivative 474,629 Not disclosed Strike: $4.42 Not disclosed
Disclosure

SEC source: 0000899243-22-019783 · doc4.xml · derivative · entry 12

APPLE ROBERT F · CIK 0001054942 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 474,629 shares

Expires not disclosed

F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Read SEC document
May 24, 2022 Filed May 26, 2022 17:23 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Disposition to issuerStock Option (right to buy) · Derivative 776,617 Not disclosed Strike: $2.73 Not disclosed
Disclosure

SEC source: 0000899243-22-019783 · doc4.xml · derivative · entry 11

APPLE ROBERT F · CIK 0001054942 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 776,617 shares

Expires not disclosed

F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Read SEC document
May 24, 2022 Filed May 26, 2022 17:23 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Disposition to issuerStock Option (right to buy) · Derivative 567,423 Not disclosed Strike: $2.92 Not disclosed
Disclosure

SEC source: 0000899243-22-019783 · doc4.xml · derivative · entry 10

APPLE ROBERT F · CIK 0001054942 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 567,423 shares

Expires not disclosed

F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Read SEC document
May 24, 2022 Filed May 26, 2022 17:23 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Disposition to issuerStock Option (right to buy) · Derivative 591,510 Not disclosed Strike: $2.70 Not disclosed
Disclosure

SEC source: 0000899243-22-019783 · doc4.xml · derivative · entry 9

APPLE ROBERT F · CIK 0001054942 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 591,510 shares

Expires not disclosed

F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Read SEC document
May 24, 2022 Filed May 26, 2022 17:23 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Disposition to issuerStock Option (right to buy) · Derivative 725,751 Not disclosed Strike: $2.66 Not disclosed
Disclosure

SEC source: 0000899243-22-019783 · doc4.xml · derivative · entry 8

APPLE ROBERT F · CIK 0001054942 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 725,751 shares

Expires not disclosed

F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Read SEC document
May 24, 2022 Filed May 26, 2022 17:23 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Disposition to issuerStock Option (right to buy) · Derivative 773,700 Not disclosed Strike: $1.12 Not disclosed
Disclosure

SEC source: 0000899243-22-019783 · doc4.xml · derivative · entry 7

APPLE ROBERT F · CIK 0001054942 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 773,700 shares

Expires not disclosed

F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Read SEC document
May 24, 2022 Filed May 26, 2022 17:23 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Disposition to issuerStock Option (right to buy) · Derivative 288,786 Not disclosed Strike: $2.18 Not disclosed
Disclosure

SEC source: 0000899243-22-019783 · doc4.xml · derivative · entry 6

APPLE ROBERT F · CIK 0001054942 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 288,786 shares

Expires not disclosed

F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Read SEC document
May 24, 2022 Filed May 26, 2022 17:23 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Disposition to issuerStock Option (right to buy) · Derivative 56,300 Not disclosed Strike: $3.09 Not disclosed
Disclosure

SEC source: 0000899243-22-019783 · doc4.xml · derivative · entry 5

APPLE ROBERT F · CIK 0001054942 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 56,300 shares

Expires not disclosed

F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Read SEC document
May 24, 2022 Filed May 26, 2022 17:23 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Disposition to issuerStock Option (right to buy) · Derivative 21,658 Not disclosed Strike: $4.26 Not disclosed
Disclosure

SEC source: 0000899243-22-019783 · doc4.xml · derivative · entry 4

APPLE ROBERT F · CIK 0001054942 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,658 shares

Expires not disclosed

F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Read SEC document
May 24, 2022 Filed May 26, 2022 17:23 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Disposition to issuerCommon Stock 374,099 $5.60 $2,094,954.40
Disclosure

SEC source: 0000899243-22-019783 · doc4.xml · nonDerivative · entry 3

APPLE ROBERT F · CIK 0001054942 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F4 · security: Each Company performance restricted stock unit ("Company PSU") means any performance stock unit granted under the Company Equity Plan. At the Effective Time, each Company PSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company PSU (at the target level of performance) immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").

F2 · kind: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

Read SEC document
May 24, 2022 Filed May 26, 2022 17:23 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Disposition to issuerCommon Stock 611,667 $5.60 $3,425,335.20
Disclosure

SEC source: 0000899243-22-019783 · doc4.xml · nonDerivative · entry 2

APPLE ROBERT F · CIK 0001054942 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F3 · security: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").

F2 · kind: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

Read SEC document
May 24, 2022 Filed May 26, 2022 17:23 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Disposition to issuerCommon Stock 1,876,693 $5.60 $10,509,480.80
Disclosure

SEC source: 0000899243-22-019783 · doc4.xml · nonDerivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").

F2 · kind: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

Read SEC document
March 03, 2022 Filed Mar 4, 2022 18:38 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Tax withholdingCommon Stock 37,695 $3.80 $143,241.00
Disclosure

SEC source: 0001016169-22-000035 · wf-form4_164643709286132.xml · nonDerivative · entry 2

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,488,360

F1 · security: On June 13, 2019, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 3, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold.

Read SEC document
March 03, 2022 Filed Mar 4, 2022 18:38 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 GrantCommon Stock 86,814 $0.00 $0.00
Disclosure

SEC source: 0001016169-22-000035 · wf-form4_164643709286132.xml · nonDerivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,526,055

F1 · security: On June 13, 2019, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 3, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold.

Read SEC document
February 16, 2022 Filed Feb 18, 2022 19:13 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Tax withholdingCommon Stock 34,282 $3.66 $125,472.12
Disclosure

SEC source: 0001016169-22-000012 · wf-form4_164522957417097.xml · nonDerivative · entry 2

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,439,241

F1 · security: On June 13, 2019, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on February 16, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold.

Read SEC document
February 16, 2022 Filed Feb 18, 2022 19:13 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 GrantCommon Stock 76,893 $0.00 $0.00
Disclosure

SEC source: 0001016169-22-000012 · wf-form4_164522957417097.xml · nonDerivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,473,523

F1 · security: On June 13, 2019, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on February 16, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold.

Read SEC document
June 13, 2021 Filed Jun 14, 2021 18:20 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Tax withholdingCommon Stock 40,892 $4.45 $181,969.40
Disclosure

SEC source: 0001209191-21-040326 · doc4.xml · nonDerivative · entry 3

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,396,630

F2 · kind: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

F2 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

F2 · acquired: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

Read SEC document
June 11, 2021 Filed Jun 14, 2021 18:20 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Tax withholdingCommon Stock 58,317 $4.45 $259,510.65
Disclosure

SEC source: 0001209191-21-040326 · doc4.xml · nonDerivative · entry 2

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,437,522

F2 · kind: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

F2 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

F2 · acquired: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

Read SEC document
June 10, 2021 Filed Jun 14, 2021 18:20 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 GrantStock Option (right to buy) · Derivative 474,629 $0.00 Strike: $4.42 $0.00
Disclosure

SEC source: 0001209191-21-040326 · doc4.xml · derivative · entry 4

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 474,629

Underlying: Common Stock · 474,629 shares

Expires 2031-06-10

F3 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan.

F4 · derivative.exercise_date: The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date.

Read SEC document
June 10, 2021 Filed Jun 14, 2021 18:20 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 GrantCommon Stock 248,869 $4.42 $1,100,000.98
Disclosure

SEC source: 0001209191-21-040326 · doc4.xml · nonDerivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,495,839

F1 · shares: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant.

Read SEC document
June 08, 2021 Filed Jun 10, 2021 17:37 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Tax withholdingCommon Stock 44,223 $4.39 $194,138.97
Disclosure

SEC source: 0001209191-21-039590 · doc4.xml · nonDerivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,246,970

F1 · kind: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

F1 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

F1 · acquired: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

Read SEC document
March 01, 2021 Filed Mar 3, 2021 18:31 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Tax withholdingCommon Stock 66,330 $4.50 $298,485.00
Disclosure

SEC source: 0001209191-21-017260 · doc4.xml · nonDerivative · entry 2

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,291,193

F1 · kind: On June 8, 2018, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 1, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold.

Read SEC document
March 01, 2021 Filed Mar 3, 2021 18:31 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 GrantCommon Stock 152,763 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-017260 · doc4.xml · nonDerivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,357,523

F1 · kind: On June 8, 2018, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 1, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 19:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Exercise / conversionStock Option (right to buy) · Derivative 250,000 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-21-012547 · doc4.xml · derivative · entry 10

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 250,000 shares

Expires 2026-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The options vested in equal quarterly installments over three years from the grant date of March 10, 2016.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 19:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 SaleCommon Stock 241,960 $5.00 $1,209,800.00
Disclosure

SEC source: 0001209191-21-012547 · doc4.xml · nonDerivative · entry 8

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,204,760

F3 · kind: This sale of common stock was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 19:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 SaleCommon Stock 17,844 $5.01 $89,398.44
Disclosure

SEC source: 0001209191-21-012547 · doc4.xml · nonDerivative · entry 7

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,446,720

F2 · kind: This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 19:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 SaleCommon Stock 232,156 $5.00 $1,160,780.00
Disclosure

SEC source: 0001209191-21-012547 · doc4.xml · nonDerivative · entry 6

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,464,564

F2 · kind: This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 19:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Exercise / conversionCommon Stock 250,000 $0.88 $220,000.00
Disclosure

SEC source: 0001209191-21-012547 · doc4.xml · nonDerivative · entry 5

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,696,720

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 17, 2021 Filed Feb 19, 2021 19:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Exercise / conversionStock Option (right to buy) · Derivative 5,519 $0.00 Strike: $2.62 $0.00
Disclosure

SEC source: 0001209191-21-012547 · doc4.xml · derivative · entry 9

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,519 shares

Expires 2025-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: The options vested in equal quarterly installments over one year from the grant date of March 10, 2015.

Read SEC document
February 17, 2021 Filed Feb 19, 2021 19:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 SaleCommon Stock 5,519 $4.75 $26,215.25
Disclosure

SEC source: 0001209191-21-012547 · doc4.xml · nonDerivative · entry 4

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,446,720

F2 · kind: This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 17, 2021 Filed Feb 19, 2021 19:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Exercise / conversionCommon Stock 5,519 $2.62 $14,459.78
Disclosure

SEC source: 0001209191-21-012547 · doc4.xml · nonDerivative · entry 3

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,452,239

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 17, 2021 Filed Feb 19, 2021 19:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Tax withholdingCommon Stock 116,313 $4.73 $550,160.49
Disclosure

SEC source: 0001209191-21-012547 · doc4.xml · nonDerivative · entry 2

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,446,720

F1 · kind: On June 8, 2018, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, which was certified and vested on February 17, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold.

Read SEC document
February 17, 2021 Filed Feb 19, 2021 19:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 GrantCommon Stock 267,878 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-012547 · doc4.xml · nonDerivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,563,033

F1 · kind: On June 8, 2018, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, which was certified and vested on February 17, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold.

Read SEC document
February 10, 2021 Filed Feb 10, 2021 20:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Exercise / conversionStock Option (right to buy) · Derivative 7,278 $0.00 Strike: $2.62 $0.00
Disclosure

SEC source: 0001209191-21-009464 · doc4.xml · derivative · entry 9

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,797 shares

Expires 2025-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · derivative.exercise_date: The options vested in equal quarterly installments over one year from the grant date of March 10, 2015.

Read SEC document
February 10, 2021 Filed Feb 10, 2021 20:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 SaleCommon Stock 7,278 $4.75 $34,570.50
Disclosure

SEC source: 0001209191-21-009464 · doc4.xml · nonDerivative · entry 6

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,295,155

F1 · kind: The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 10, 2021 Filed Feb 10, 2021 20:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Exercise / conversionCommon Stock 7,278 $2.62 $19,068.36
Disclosure

SEC source: 0001209191-21-009464 · doc4.xml · nonDerivative · entry 5

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,302,433

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 09, 2021 Filed Feb 10, 2021 20:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Exercise / conversionStock Option (right to buy) · Derivative 49,129 $0.00 Strike: $2.62 $0.00
Disclosure

SEC source: 0001209191-21-009464 · doc4.xml · derivative · entry 8

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 49,129 shares

Expires 2025-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · derivative.exercise_date: The options vested in equal quarterly installments over one year from the grant date of March 10, 2015.

Read SEC document
February 09, 2021 Filed Feb 10, 2021 20:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 SaleCommon Stock 49,129 $4.75 $233,362.75
Disclosure

SEC source: 0001209191-21-009464 · doc4.xml · nonDerivative · entry 4

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,295,155

F1 · kind: The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 09, 2021 Filed Feb 10, 2021 20:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Exercise / conversionCommon Stock 49,129 $2.62 $128,717.98
Disclosure

SEC source: 0001209191-21-009464 · doc4.xml · nonDerivative · entry 3

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,344,284

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 20:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Exercise / conversionStock Option (right to buy) · Derivative 33,574 $0.00 Strike: $2.62 $0.00
Disclosure

SEC source: 0001209191-21-009464 · doc4.xml · derivative · entry 7

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,574 shares

Expires 2025-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · derivative.exercise_date: The options vested in equal quarterly installments over one year from the grant date of March 10, 2015.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 20:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 SaleCommon Stock 33,574 $4.75 $159,476.50
Disclosure

SEC source: 0001209191-21-009464 · doc4.xml · nonDerivative · entry 2

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,295,155

F1 · kind: The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 20:11 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Exercise / conversionCommon Stock 33,574 $2.62 $87,963.88
Disclosure

SEC source: 0001209191-21-009464 · doc4.xml · nonDerivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,328,729

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
June 13, 2020 Filed Jun 15, 2020 19:12 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Tax withholdingCommon Stock 40,892 $2.78 $113,679.76
Disclosure

SEC source: 0001209191-20-036786 · doc4.xml · nonDerivative · entry 2

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,295,155

F2 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

Read SEC document
June 11, 2020 Filed Jun 15, 2020 19:12 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 GrantStock Option (right to buy) · Derivative 776,617 $0.00 Strike: $2.73 $0.00
Disclosure

SEC source: 0001209191-20-036786 · doc4.xml · derivative · entry 3

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 776,617

Underlying: Common Stock · 776,617 shares

Expires 2030-06-11

F3 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan.

F4 · derivative.exercise_date: The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date.

Read SEC document
June 11, 2020 Filed Jun 15, 2020 19:12 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 GrantCommon Stock 402,930 $2.73 $1,099,998.90
Disclosure

SEC source: 0001209191-20-036786 · doc4.xml · nonDerivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,336,047

F1 · shares: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant.

Read SEC document
June 08, 2020 Filed Jun 9, 2020 18:24 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Tax withholdingCommon Stock 44,223 $3.13 $138,417.99
Disclosure

SEC source: 0001209191-20-035377 · doc4.xml · nonDerivative · entry 2

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,933,117

F1 · kind: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

F1 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

F1 · acquired: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

Read SEC document
June 07, 2020 Filed Jun 9, 2020 18:24 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Tax withholdingCommon Stock 48,936 $3.12 $152,680.32
Disclosure

SEC source: 0001209191-20-035377 · doc4.xml · nonDerivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,977,340

F1 · kind: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

F1 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

F1 · acquired: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

Read SEC document
February 19, 2020 Filed Feb 21, 2020 18:24 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 Tax withholdingCommon Stock 90,397 $3.53 $319,101.41
Disclosure

SEC source: 0001209191-20-011709 · doc4.xml · nonDerivative · entry 2

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,026,276

F1 · kind: On August 25, 2017, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2019. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 19, 2020. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award.

Read SEC document
February 19, 2020 Filed Feb 21, 2020 18:24 UTC ANTARES PHARMA, INC. ATRS · Entity 126887 GrantCommon Stock 210,782 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-011709 · doc4.xml · nonDerivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,116,673

F1 · kind: On August 25, 2017, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2019. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 19, 2020. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.